23.05.20|Sophie Shulman and Golan HazaniArie Belldegrun, chairman of UroGen Pharma, talks about catching Covid-19 and gaining FDA approval in the midst of a global pandemic
24.04.19|CTechThe two companies will collaborate on the research of a “therapeutic area of mutual interest”
24.01.19|Lilach BaumerGoldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering
12.07.18|Amir RosenbaumKite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections
08.11.17|Lilach BaumerAllergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen